Drug intelligence / Profile preview

Aquabuz

Development stage: Unknown
Lead developer: Genspec Lifesciences
Modality: Small Molecules
Administration: Oral

Overview

Aquabuz is a nutraceutical health supplement developed by Genspec Lifesciences, designed to address calcium and vitamin D deficiencies and support overall bone and mineral health. It is a combination product containing Aquamin, a multi-mineral complex derived from red seaweed (*Lithothamnion* species) that is rich in calcium and magnesium, and Vitamin D3 (cholecalciferol). The supplement works by providing a bioavailable source of essential minerals and enhancing calcium absorption through the action of Vitamin D3, thereby improving bone density, joint strength, and muscle health. It is typically administered orally in tablet form.

Brand names: Aquabuz
Other names: Aquamin + Vitamin D3

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Aquabuz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aquabuz.

Explore the full profile